JP2009544318A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544318A5 JP2009544318A5 JP2009521850A JP2009521850A JP2009544318A5 JP 2009544318 A5 JP2009544318 A5 JP 2009544318A5 JP 2009521850 A JP2009521850 A JP 2009521850A JP 2009521850 A JP2009521850 A JP 2009521850A JP 2009544318 A5 JP2009544318 A5 JP 2009544318A5
- Authority
- JP
- Japan
- Prior art keywords
- influenza virus
- polypeptide
- particle
- virus
- chimeric influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010022000 influenza Diseases 0.000 claims 27
- 229920001184 polypeptide Polymers 0.000 claims 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- 239000002245 particle Substances 0.000 claims 26
- 101710154606 Hemagglutinin Proteins 0.000 claims 11
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 11
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 11
- 101710176177 Protein A56 Proteins 0.000 claims 11
- 239000000185 hemagglutinin Substances 0.000 claims 11
- 102000005348 Neuraminidase Human genes 0.000 claims 10
- 108010006232 Neuraminidase Proteins 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 239000013604 expression vector Substances 0.000 claims 7
- 241000712461 unidentified influenza virus Species 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 241000238631 Hexapoda Species 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 229960001438 immunostimulant agent Drugs 0.000 claims 2
- 239000003022 immunostimulating agent Substances 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000001681 protective effect Effects 0.000 claims 2
- 241000701447 unidentified baculovirus Species 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 241001664176 Alpharetrovirus Species 0.000 claims 1
- 241001231757 Betaretrovirus Species 0.000 claims 1
- 241001663879 Deltaretrovirus Species 0.000 claims 1
- 241001663880 Gammaretrovirus Species 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 241000714177 Murine leukemia virus Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83420006P | 2006-07-27 | 2006-07-27 | |
| US60/834,200 | 2006-07-27 | ||
| US87892007P | 2007-01-05 | 2007-01-05 | |
| US60/878,920 | 2007-01-05 | ||
| PCT/US2007/016900 WO2008094197A2 (en) | 2006-07-27 | 2007-07-27 | Chimeric influenza virus-like particles |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009544318A JP2009544318A (ja) | 2009-12-17 |
| JP2009544318A5 true JP2009544318A5 (enExample) | 2010-08-19 |
| JP5683811B2 JP5683811B2 (ja) | 2015-03-11 |
Family
ID=39674641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009521850A Expired - Fee Related JP5683811B2 (ja) | 2006-07-27 | 2007-07-27 | キメラインフルエンザウイルス様粒子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9439959B2 (enExample) |
| EP (1) | EP2044198A4 (enExample) |
| JP (1) | JP5683811B2 (enExample) |
| AU (1) | AU2007345768B2 (enExample) |
| CA (1) | CA2659275C (enExample) |
| WO (1) | WO2008094197A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2044224A4 (en) * | 2006-07-27 | 2011-04-13 | Ligocyte Pharmaceuticals Inc | CHIMERIC VIRUS TYPE PARTICLES |
| EP2134360B1 (en) | 2007-03-14 | 2015-11-18 | Takeda Vaccines, Inc. | Virus like particle purification |
| AU2009319979B2 (en) * | 2008-11-03 | 2016-10-20 | Takeda Vaccines, Inc. | Improved methods for isolating enveloped virus-based VLPs free of infectious agents |
| AU2008364200B2 (en) * | 2008-11-19 | 2016-01-28 | Laboratorio Avi-Mex, S.A. De C.V. | Recombinant inactivated viral vector vaccine |
| US20120121710A1 (en) | 2009-03-27 | 2012-05-17 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Mucosal Immunization |
| JP5762307B2 (ja) * | 2009-03-31 | 2015-08-12 | 国立感染症研究所長 | 経鼻投与用ワクチンを用いるインフルエンザの予防方法 |
| KR20120018783A (ko) * | 2009-05-01 | 2012-03-05 | 레드바이오텍 아게 | 다중 유전자 벡터에 의해 암호화된 재조합 바이러스-유사 입자 |
| ES2566361T3 (es) | 2009-07-02 | 2016-04-12 | Massachusetts Institute Of Technology | Composiciones y métodos para diagnosticar y/o tratar una infección gripal |
| WO2011056899A2 (en) * | 2009-11-03 | 2011-05-12 | Ligocyte Pharmaceuticals, Inc. | Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps |
| WO2011057134A1 (en) | 2009-11-05 | 2011-05-12 | Novici Biotech Llc | Generation of antigenic virus-like particles through protein-protein linkages |
| WO2011090712A2 (en) * | 2009-12-28 | 2011-07-28 | Ligocyte Pharmaceuticals, Inc. | Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions |
| NZ601609A (en) * | 2010-01-21 | 2014-08-29 | Univ Arkansas | Vaccine vectors and methods of enhancing immune responses |
| AR081809A1 (es) * | 2010-03-29 | 2012-10-24 | Inst Nat Sante Rech Med | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas |
| WO2012040406A2 (en) | 2010-09-21 | 2012-03-29 | Massachusetts Institute Of Technology | Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines |
| WO2012047941A2 (en) | 2010-10-04 | 2012-04-12 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| JOP20130186B1 (ar) | 2012-06-22 | 2021-08-17 | Takeda Vaccines Montana Inc | تنقية الجزيئات الشبيهة بالفيروسات |
| JP2015015931A (ja) * | 2013-07-12 | 2015-01-29 | 株式会社Ｕｍｎファーマ | ウイルス様粒子を含む培養物の製造方法 |
| KR101745472B1 (ko) * | 2015-04-15 | 2017-06-12 | 대한민국 | 조류인플루엔자 바이러스의 세포 감염을 저해하는 물질을 선별하는 방법 |
| US10682398B2 (en) | 2016-05-03 | 2020-06-16 | The Texas A&M University System | Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same |
| US11116832B2 (en) | 2016-06-03 | 2021-09-14 | Sanofi Pasteur Inc. | Modification of engineered influenza hemagglutinin polypeptides |
| JPWO2021085650A1 (enExample) * | 2019-10-31 | 2021-05-06 | ||
| CN113827715B (zh) * | 2020-06-23 | 2024-07-05 | 普莱柯生物工程股份有限公司 | 一种抗h7亚型和h5亚型禽流感病毒的疫苗组合物、及其制备方法和应用 |
| CN113264989A (zh) * | 2021-05-17 | 2021-08-17 | 吉林大学 | 一种h9n2亚型禽流感嵌合病毒样颗粒制备方法及应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485729B1 (en) * | 1993-09-13 | 2002-11-26 | Protein Sciences Corporation | Neuraminidase-supplemented compositions |
| DE69735376T2 (de) * | 1996-11-26 | 2006-12-14 | Stressgen Biotechnologies Corp., Victoria | Fusionsproteine, die stressproteine beinhalten, zum hervorrufen einer immunantwort |
| US6099847A (en) | 1997-05-15 | 2000-08-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric Gag pseudovirions |
| GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| JP2002533124A (ja) * | 1998-12-31 | 2002-10-08 | カイロン コーポレイション | Ｈｉｖポリペプチドの改善された発現およびウイルス様粒子の生成 |
| US20040105871A1 (en) * | 2000-03-02 | 2004-06-03 | Robinson Harriet L. | Compositions and methods for generating an immune response |
| KR100877019B1 (ko) * | 2000-06-23 | 2009-01-07 | 와이어쓰 홀딩스 코포레이션 | 야생형 및 키메릭 인플루엔자 바이러스성입자(브이엘피)의 조립 |
| CN1468301A (zh) | 2000-06-23 | 2004-01-14 | 从邻近启动子的基因表达保护性抗原的呼吸道合胞病毒疫苗 | |
| EP1298204B1 (en) | 2000-06-28 | 2007-04-04 | Fuji Nihon Seito Corporation | Novel inulin synthase and process for producing inulin by using the same |
| EP1201750A1 (en) | 2000-10-26 | 2002-05-02 | Genopoietic | Synthetic viruses and uses thereof |
| WO2002090549A2 (en) | 2001-03-12 | 2002-11-14 | Proteologics Inc. | Compositions and methods for the modulation of viral maturation |
| US20030198621A1 (en) | 2001-07-05 | 2003-10-23 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof |
| GB0202569D0 (en) * | 2002-02-04 | 2002-03-20 | Oxford Biomedica Ltd | Delivery means |
| NZ536499A (en) | 2002-05-16 | 2008-04-30 | Bavarian Nordic As | Fusion protein comprising the amino acid sequence of at least four different HIV proteins selected from Vif, Vpr, Vpu, Vpx, Rev, Tat and Nef, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini |
| US9045727B2 (en) | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| WO2004042001A2 (en) * | 2002-05-17 | 2004-05-21 | Emory University | Virus-like particles, methods of preparation, and immonogenic compositions |
| CA2486282C (en) * | 2002-05-17 | 2012-04-10 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
| CA2488856A1 (en) | 2002-06-20 | 2003-12-31 | Cytos Biotechnology Ag | Packaged virus-like particles for use as adjuvants: method of preparation and use |
| GB0226722D0 (en) * | 2002-11-15 | 2002-12-24 | Glaxo Group Ltd | Vaccine |
| US6910730B2 (en) * | 2002-12-25 | 2005-06-28 | Shiroki Corporation | Mounting device for mounting a cable-operated window regulator |
| US8080255B2 (en) * | 2003-07-11 | 2011-12-20 | Novavax Inc. | Functional influenza virus like particles (VLPs) |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| US8574590B2 (en) * | 2003-07-30 | 2013-11-05 | Integral Molecular, Inc. | Lipoparticles comprising proteins, methods of making, and using the same |
| WO2006039701A1 (en) * | 2004-10-01 | 2006-04-13 | University Of South Florida | Flagellin-based adjuvants and vaccines |
| RU2483751C2 (ru) * | 2005-10-18 | 2013-06-10 | Новавакс, Инк. | ФУНКЦИОНАЛЬНЫЕ ВИРУСОПОДОБНЫЕ ЧАСТИЦЫ ГРИППА (VLPs) |
| US8437251B2 (en) | 2005-12-22 | 2013-05-07 | Qualcomm Incorporated | Methods and apparatus for communicating transmission backlog information |
| EP2044224A4 (en) * | 2006-07-27 | 2011-04-13 | Ligocyte Pharmaceuticals Inc | CHIMERIC VIRUS TYPE PARTICLES |
| CA2615372A1 (en) * | 2007-07-13 | 2009-01-13 | Marc-Andre D'aoust | Influenza virus-like particles (vlps) comprising hemagglutinin |
| ES2668836T3 (es) * | 2008-08-08 | 2018-05-22 | Takeda Vaccines, Inc. | Partículas similivíricas que comprenden secuencias de aminoácidos de la cápside compuestas para reactividad cruzada potenciada |
-
2007
- 2007-07-27 WO PCT/US2007/016900 patent/WO2008094197A2/en not_active Ceased
- 2007-07-27 EP EP07872585A patent/EP2044198A4/en not_active Withdrawn
- 2007-07-27 AU AU2007345768A patent/AU2007345768B2/en not_active Ceased
- 2007-07-27 US US12/375,376 patent/US9439959B2/en not_active Expired - Fee Related
- 2007-07-27 JP JP2009521850A patent/JP5683811B2/ja not_active Expired - Fee Related
- 2007-07-27 CA CA2659275A patent/CA2659275C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544318A5 (enExample) | ||
| JP7250878B2 (ja) | 新規多価ナノ粒子に基づくワクチン | |
| Panahi et al. | An overview on the treatments and prevention against COVID-19 | |
| RU2609645C2 (ru) | Экспрессионные системы | |
| Altenburg et al. | Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases | |
| McMahon et al. | Vaccination with viral vectors expressing chimeric hemagglutinin, NP and M1 antigens protects ferrets against influenza virus challenge | |
| Lundstrom | Alphavirus-based vaccines | |
| Hessel et al. | MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses | |
| JP2010535026A5 (enExample) | ||
| EP3676285B1 (en) | A vaccine for use in the prophylaxis and/or treatment of a disease | |
| JP2016534034A5 (enExample) | ||
| JP2020517635A5 (enExample) | ||
| Fan et al. | Targeting the HA2 subunit of influenza A virus hemagglutinin via CD40L provides universal protection against diverse subtypes | |
| JP2016513115A5 (enExample) | ||
| Carascal et al. | Recent progress in recombinant influenza vaccine development toward heterosubtypic immune response | |
| JP2013216685A5 (enExample) | ||
| MX2020000221A (es) | Secuencias de aminoacidos y de acidos nucleicos de adenovirus de grandes simios no humanos, vectores que contienen las mismas y usos de las mismas. | |
| JP2013510091A5 (enExample) | ||
| Singh et al. | An alphavirus-based therapeutic cancer vaccine: from design to clinical trial | |
| RU2015135890A (ru) | Композиция вакцины | |
| CN104271594A (zh) | 用于初免-加强疫苗的水疱性口炎病毒 | |
| Spunde et al. | Recombinant viral vectors for therapeutic programming of tumour microenvironment: Advantages and limitations | |
| JP2016513471A5 (enExample) | ||
| CA3023791A1 (en) | Combination prime: boost therapy | |
| KR20210114379A (ko) | 융합 단백질 |